Quess Corp has received approval from the National Company Law Tribunal (NCLT) for a three-way demerger, allowing the business services provider to create three publicly listed entities. The approval marks a significant step in Quess Corp's restructuring, with share allotment and listing of the new firms expected to occur within two months. Following the announcement, Quess Corp's share price rose by 6%. Other stocks in focus include Eris Lifesciences, which is transferring two arms to Eris Therapeutics for ₹862 crore, and Jindal Stainless, which is divesting a 26% stake in Jindal Coke. Market analysts are monitoring these developments closely as they prepare for trading on March 7, 2025.